泽泻汤合二陈汤化裁治疗非酒精性脂肪肝痰浊内阻证的临床研究  

Clinical Study on Curative Effect of Non-Alcoholic Fatty Liver with Phlegm Turbidity Resistance Syndrome Treated with Zexie Decoction(泽泻汤)and Erchen Decoction(二陈汤)

作　　者：苏庆珠 李显筑 孟薇 SU Qingzhu;LI Xianzhu;MENG Wei(Department of Gastroenterology,Qiqihar Chinese Medicine Hospital,Qiqihar,Heilongjiang 161005;Heilongjiang Academy of Chinese Medicine Sciences,Harbin,Heilongjiang 150036)

机构地区：[1]齐齐哈尔市中医医院消化内科,黑龙江齐齐哈尔161005 [2]黑龙江省中医药科学院,黑龙江哈尔滨150036

出　　处：《中国中医药科技》2025年第1期11-15,共5页Chinese Journal of Traditional Medical Science and Technology

基　　金：黑龙江省中医药管理局科研项目(ZHY2020-010)。

摘　　要：目的:观察泽泻汤合二陈汤化裁治疗非酒精性脂肪肝痰浊内阻证患者的临床疗效及其对人细胞角蛋白18(CK-18)、转化生长因子-β1(TGF-β1)的影响。方法:选取2022年5月—2024年1月于齐齐哈尔市中医医院消化内科门诊招募的非酒精性脂肪肝痰浊内阻证患者84例,随机分为观察组和对照组,每组42例。对照组给予多烯磷脂酰胆碱胶囊治疗,观察组加用泽泻汤合二陈汤化裁治疗,2组疗程均为8周。比较2组患者的临床疗效、治疗前后中医证候积分、肝脏受控衰减参数(CAP)、肝功能、血脂以及CK-18、TGF-β1水平。结果:治疗8周后,观察组总有效率为83.33%,高于对照组的64.29%(P<0.05);2组患者中医证候积分较治疗前均显著降低(P<0.01),且观察组低于对照组(P<0.01);2组患者CAP值较治疗前均显著降低(P<0.01),且观察组低于对照组(P<0.01);2组患者ALT、AST、GGT、TC、TG水平较治疗前显著降低(P<0.01),且观察组低于对照组(P<0.01);2组患者CK-18和TGF-β1水平较治疗前显著降低(P<0.01),且观察组低于对照组(P<0.01)。结论:泽泻汤合二陈汤化裁治疗非酒精性脂肪肝痰浊内阻证患者效果显著,能够显著改善痰浊内阻证候,改善肝功能和血脂水平,降低CAP值和CK-18、TGF-β1水平。Objective:To observe the curative effect of Zexie Decoction combined with Erchen Decoction in the treatment of patients with non-alcoholic fatty liver disease(NAFLD)with phlegm turbidity resistance syndrome and its effects on human cytokeratin 18(CK-18)and transforming growth factor-β1(TGF-β1).Methods:84 patients with NAFLD of phlegm turbidity resistance syndrome recruited were randomly divided into an observation group and a control group,with 42 patients in each group.The control group was treated with Polyene phosphatidylcholine capsules,while the observation group was treated with Zexie Decoction and Erchen Decoction modified.The treatment course for both groups was 8 weeks.Compare the clinical efficacy,TCM syndrome scores before and after treatment,controlled attenuation parameters(CAP)of the liver,liver function indexes,blood lipid,as well as CK-18 and TGF-β1 levels between two groups.Results:After 8 weeks of treatment,he total effective rate of the observation group was 83.33%,which was higher than the 64.29%of the control group(P<0.05);The TCM syndrome scores of both groups were significantly reduced compared to before treatment(P<0.01),and the syndrome scores of observation group was lower than that the control group(P<0.01);The CAP values of both groups were significantly reduced compared to before treatment(P<0.01),and the CAP of observation group was lower than that of the control group(P<0.01);The levels of ALT,AST,GGT,TC,and TG in two groups were significantly reduced compared to before treatment(P<0.01),and the those in observation group were lower than those of the control group(P<0.01);The levels of CK-18 and TGF-β1 in the two groups were significantly reduced compared to before treatment(P<0.01),and the levels of CK-18 and TGF-β1 of the observation group were lower than those of the control group(P<0.01).Conclusion:The combination of Zexie Decoction and Erchen Decoction has a significant effect on the treatment of patients with NAFLD of phlegm turbidity resistance syndrome.It can significan

关 键 词：非酒精性脂肪肝 痰浊内阻证 泽泻汤 二陈汤 肝脏受控衰减参数 肝功能 血脂 CK-18 TGF-Β1 

分 类 号：R259[医药卫生—中西医结合]